Matthew R. Smith

Publications494
h-index83
Citations31,283
Highly Influential Citations1,112
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • K. Fizazi
  • 1,002 Publications • 52,105 Citations
  • F. Saad
  • 1,321 Publications • 54,850 Citations
  • E. Small
  • 788 Publications • 53,203 Citations
  • J. D. de Bono
  • 792 Publications • 65,817 Citations
  • Publications
  • Influence
Abiraterone in metastatic prostate cancer without previous chemotherapy.
TLDR
Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer.
View on PubMed
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
View on Elsevier
NCCN clinical practice guidelines in oncology: prostate cancer.
View on PubMed
Apalutamide Treatment and Metastasis‐free Survival in Prostate Cancer
TLDR
Among men with nonmetastatic castration‐resistant prostate cancer, metastasis‐free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.
View on Wolters Kluwer
Adverse effects of androgen deprivation therapy and strategies to mitigate them.
View on PubMed
Changes in body composition during androgen deprivation therapy for prostate cancer.
TLDR
GnRH agonists increase weight and percentage fat body mass and decrease percentage lean body mass, fat distribution, and muscle size in men with nonmetastatic prostate cancer.
View on PubMed
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
TLDR
GnRH agonist treatment for men with locoregional prostate cancer may be associated with an increased risk of incident diabetes and cardiovascular disease and the benefits of GnRH agonists should be weighed against these potential risks.
View on PubMed
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
TLDR
Zoledronic acid increases bone mineral density in the hip and spine during androgen deprivation therapy for nonmetastatic prostate cancer and was well tolerated.
View on PubMed
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a…
View on PubMed
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
View on Elsevier
...
...